tbuckley/cabot-search huggingface dataset:
Editorial: Changing patterns of cancer.
Journal: BMJ (1976)

Changing patterns of cancerCancer registration is a powerful epidemiological tool whose usefulness improves with time: for it is only with the passage of time that changes in the pattern of the incidence and mort- ality of cancers can be seen; the value of treatment and pre- vention assessed; and the subtle effects of environmental cancers brought to light.Usually changes in incidence occur almost imperceptibly and make little difference to the clinician; but occasionally they may be sufficiently pronounced to be noticeable in a single surgeon's experience, as was recently reported by Belcher' from the London Chest Hospital.In his surgical series of 1478 cases of carcinoma of the bronchus from 1950 to 1970 the peak age was 56-60 in the first decade and had risen to 61-65 in the second.The proportion of men over 65 among those treated by surgery was 12",, in 1950-5 and 17",, in 1970-4.In women a similar trend was evident, so that in 1970-4 32",, of his women patients were over 65.Clearly a surgical series may be biased by the surgeon's criteria for selection for surgery.This possibility was examined and found not to be the cause of the change of pattern of patients presenting for treatment, which showed two trends: that more patients were requiring treatment, and that they were getting older.Reviewing the national figures for England and Wales, Belcher confirmed a progressive change in line with predic- tions made a few years ago by Springett2 and Langston.3The number of men aged 60-69 alive in England and Wales had increased between 1950 and 1970 by 640 000, and it was this older group that largely accounted for the increase of deaths from lung cancer during this period.The overall rate per 100 000 for lung cancer changed from 49 to 99-9 in men and from 9 0 to 20-6 in women in the 20 years, with an upward trend in the peak age incidence.There were two other im-
MISCELLANY.
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PATHOLOGIC EFFECTS OF CRAB LICE
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
I enjoy my current career but I feel unfulfilled by what I can offer patients. I believe very strongly that I could be a good doctor and I have a particular interest in paediatrics. I'm 36 with a young family and my concerns are that if I am fortunate enough to gain entry on to a graduate medicine course in 2008, will my career prospects be compromised by my late start?
Authors: Luci Etheridge
Journal: BMJ (2007)

Have a career related problem that needs answering? Can9t find the person to point you in the right direction? Log on to the Advice Zone for reliable medical careers advice. You can post a question or see if one of our 300 advisers has already answered a similar question. Here is a selection of questions and answers posted on the site <b>www.bmjcareers.com/advicezone</b>
Primary prevention of venous thromboembolic events (VTE) in cancer patients: An American survey study
Authors: S. R. Deitcher
Journal: Journal of Clinical Oncology (2004)

8086 Background: Optimal care of and research involving cancer patients at risk for and with documented VTE require insight into thrombosis risk factors plus risks and benefits of anticoagulation (AC). Formal quantification of oncologist attitudes towards VTE has been lacking. Methods: We performed a two-phase, web- and fax-based survey study of American oncologists, including 28 questions that asked respondents to quantify the “necessity” and “appropriateness” of VTE prophylaxis or treatment in several clinical scenarios. Mean responses provided assessment of group opinion. Results: In Phase I (n=507), 61% and 63% indicated regular prescription of inpatient and central line VTE prophylaxis, respectively; 39% believed that LMWHs can prolong cancer patient survival. Phase II (n=112 from 33 states) demographics: 63% private practice, 84% solid tumor focus, 79% Oncology board certified, 88% ASCO members. Respondents under-recognized known VTE risk factors (e.g. brain mets, antiangiogenesis drugs, and EPO) and high risk histologies (e.g. primary brain, lung, lymphoma, and ovary). Consensus on the necessity/appropriateness of VTE prophylaxis in cancer inpatients, outpatients, febrile neutropenia, advanced stage, and central lines was lacking. Prophylactic and treatment AC were deemed inappropriate in cancer patients without active bleeding and platelet counts < 50,000/μL. LMWHs were the preferred agents for active VTE prophylaxis in cancer inpatients and during febrile neutropenia; warfarin was preferred in those with advanced stage disease and central lines. 44% and 76% agreed that cancer patients require higher doses of thromboprophylaxis and are at higher risk for bleeding during thromboprophylaxis than non-cancer patients, respectively. Conclusions: Under-recognition of prevalent risk factors and high risk histologies and fear of bleeding especially in thrombocytopenic patients may explain the underutilization of VTE prophylaxis by American oncologists. Formal investigation of the risks and benefits of anticoagulation in several oncology settings seems indicated in order to guide clinical practice and consensus building. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Aventis
Intracranial Lesions Alleviate Disease, Intractable Pain
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Chromosome Aberrations and Their Relevance to Metal Carcinogenesis
Authors: H. Vainio, M. Sorsa
Journal: Environmental Health Perspectives (1981)

Scoring for structural chromosome abnormalities is one of the only practical methods available for detecting visual damage in human genetic material. Cytogenetic tests in vivo and in vitro have shown the clastogenic potential of a number of metals and metal compounds. The difficulties in in vivo studies lie in identifying a specific clastogen in an occupational setting, where simultaneous exposure to a number of organic and inorganic chemicals is a common phenomenon. Metals known to be carcinogens in animals also tend to possess chromosome-damaging properties, even though more extensive studies are needed before any conclusive evidence can be reached. The visible chromosomal damage produced by exposure to metal compounds should be considered as a warning indication of potentially adverse genetic and somatic effects in humans.
Erratum to: Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
Authors: Sotirios P. Fortis, Michael Sofopoulos, Nectaria N. Sotiriadou, Christoforos Haritos, Christoforos K. Vaxevanis, Eleftheria A. Anastasopoulou, Nicole Janssen, Niki Arnogiannaki, Alexandros Ardavanis, Graham Pawelec, Sonia A. Perez, Constantin N. Baxevanis
Journal: Journal for ImmunoTherapy of Cancer (2017)

[This corrects the article DOI: 10.1186/s40425-017-0240-7.].
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Authors: Pamela L. Kunz, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre, Carlos J. Suarez, James C. Yao, Matthew H. Kulke, Andrew Eugene Hendifar, James Christopher Shanks, Manisha H. Shah, Mark Zalupski, Edmond L. Schmulbach, Diane Lauren Reidy, Jonathan R. Strosberg, Peter J. O'Dwyer, Al Bowen Benson
Journal: Journal of Clinical Oncology (2018)

4004 Background: Patients with advanced pancreatic neuroendocrine tumors (pNETs) have few treatment options that yield objective tumor regression. Somatostatin analogues, everolimus, and sunitinib yield prolonged progression-free survival (PFS) but low response rates (RRs). Retrospective and small, prospective studies suggest that temozolomide-based therapies may have activity and the combination of temozolomide and capecitabine (TC) is associated with high RRs and relative long PFS. However, there are no randomized, prospective studies of these agents and this trial was initiated to establish a role for the combination of TC. Methods: E2211 was a two-arm, randomized, phase II trial comparing T (200 mg/m2 PO QD days 1-5) vs. TC (T 200 mg/m2 PO QD days 10-14; C 750 mg/m2 PO BID days 1-14) in patients with advanced pNETs. Eligibility criteria included: metastatic or unresectable, low or intermediate grade pNETs, progression within preceding 12 months, and no prior T, C, DTIC, or 5-FU. The primary endpoint was PFS; secondary endpoints were Overall Survival (OS), RR, safety, and predictive value of MGMT as evaluated by immunohistochemistry and promoter methylation. This trial had at least 81% power to detect a difference in median PFS of 9 vs. 14 months (hazard ratio of 0.64) using a two-sided log-rank test at the 0.20 significance level. Results: 144 patients were enrolled at 66 US sites between 8/2013 to 3/2016 to T (n = 72) or TC (n = 72) (intention to treat population). Median age, 62 years; women, 44%. Median PFS was 22.7 months for TC vs. 14.4 months for T (HR = 0.58, p = 0.023) and crossed the pre-specified protocol efficacy boundary. Median OS was 38.0 months for T and has not been reached for TC (HR = 0.41, p = 0.012). Median follow-up was 29 months. RR data will be presented at the meeting. The treatment was well-tolerated with expected AEs and higher rates in the combination arm. Conclusions: In E2211, TC was associated with improved PFS and OS compared to T alone in advanced low or intermediate grade pNETs. This is the first prospective randomized trial of these agents and shows the longest PFS reported for pNET-directed therapy. Clinical trial information: NCT01824875.
A cost-benefit analysis of immunization for pneumococcal pneumonia
Authors: K. M. Patrick
Journal: JAMA (1981)

To determine whether immunization against pneumococcal pneumonia could be justified on the basis of a favorable benefit to cost ratio, we evaluated the projected impact of a program of pneumococcal vaccination on the population of a health maintenance organization. Retrospective data on average provider and patient costs associated with episodes of pneumococcal pneumonia were coupled with forecasts of the likely effectiveness of currently available vaccine and its impact on anticipated incidence of pneumonia. We found that when provider-centered and patient-centered costs and benefits were added, a program of immunizing those traditionally considered to be at high risk of contracting pneumococcal pneumonia (50 years of age and older; patients with chronic diseases of the heart, liver, lungs, or kidneys; and those with diabetes mellitus) was justified on a cost-benefit basis. (<i>JAMA</i>1981;245:473-477)
The Mask of Sanity: An Attempt to Reinterpret the So-Called Psychopathic Personality
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Affiliation
Journal: JAMA (1982)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Simpler times
Authors: D. Shulkin
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Soviet Antisemitism
Authors: LAURO F. CAVAZOS
Journal: Annals of Internal Medicine (1976)

Comments and Correction1 May 1976Soviet AntisemitismLAURO F. CAVAZOS, PH.D., Dean, PAUL REICH, M.D.LAURO F. CAVAZOS, PH.D., DeanSearch for more papers by this author, PAUL REICH, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-84-5-616_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: During the past several months, there has been increasing world concern over the fate of Soviet Jewish physicians, scientists, and intellectuals who have sought to emigrate to Israel and elsewhere. Often dismissed from their jobs, barred from their laboratories, or demoted to menial tasks, they live with the fear that they will be arrested or imprisoned, perhaps in a mental hospital (1), or that permission to emigrate will never be granted to them. Some case histories will illustrate:Dr. Mikhail Shtern, former Chief of Endocrinology at Vinnitsa Hospital in the Ukraine, was recently sentenced to 8 years'...References1. CHODOFF P: Involuntary hospitalization of political dissenters in the Soviet Union. Psych Opinion 11:5, 1974 Google Scholar2. Soviet Jewish doctor gets 8 years in a bribery case. NY Times 1 January 1975, p. 38 Google Scholar3. SATTINAXELRODKOPIN AJI: Ilya Glezer's struggle (letter). Science 187:902, 1975 CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: LAURO F. CAVAZOS, PH.D., Dean; PAUL REICH, M.D. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 May 1976Volume 84, Issue 5Page: 616-617KeywordsEndocrinologyFearScientists ePublished: 1 December 2008 Issue Published: 1 May 1976 PDF downloadLoading ...
Problem Drugs
Authors: Marcus M. Reidenberg
Journal: JAMA (1995)

<i>Problem Drugs</i>is a polemic against some of the marketing practices of many members of the pharmaceutical industry and against the excessive prescribing of medications by many physicians, often in response to those marketing practices. Each chapter is a stand-alone essay about a specific alleged evil practice, ending with recommendations for action. Practices criticized include promotion of antibiotic use for people with general infections often due to organisms not responsive to antibiotics, such as viruses, and promotion of some drugs, often nonsteroidal anti-inflammatory medications, as being good for people of all ages when, in fact, the elderly are at greater risk. Some, such as urging the universal banning of antidiarrheal products containing hydroxyquinolones or strict governmental control over the claims made for vitamin preparations, are reasonable and appropriate. Others, such as the recommendation that estrogen replacement therapy "should not be recommended for widespread use by all menopausal or postmenopausal women,"
Harveian Lectures on the Mode of Death from Acute Intestinal Strangulation and Chronic Intestinal Obstruction
Authors: T. Bryant
Journal: BMJ (1884)

ITS TREATMENT. DiSCL'85ED, in Iny former lecture, the subject of intestinial strangiglationl; and I hope I well justified, in your juldgmient, my separatioii of it from the class of cases with whiclh hitherto it has beei associated, ;hiLmely, that of intestinal obstruction.I trust, mnoreover, that I made it clear to you that, WlhCII a patient dies from illtestilial straniguilation, his (leath is iiot caused by the obstruction, althoulgh obstructioti ina halve been one of its symptoms, bhit froin changes brought about in tic initestine itself, dIuie to its strangulation.In my lpreseilt lecture, the subject of ititestilial obsti-uctioli will OcCupy our attention ; and, more particularly, the way in whliel it destroys life.I shall show you what chaiiges the ilitestine ulidergoes as a result of obstruction, and how these changes tenid to kill.I sliall thesn go back, anld colnsider what affections lead up to obstructioll, alid subsequently poilit out the indications for tlCe treatmnciit of its differenit varieties.
FDA soon to license H influenzae vaccine
Authors: C. Marwick
Journal: JAMA (1985)

The first vaccine against<i>Haemophilus influenzae</i>will soon become commercially available. After at least 12 years of clinical studies, the Food and Drug Administration (FDA) is prepared to license a vaccine against this major cause of bacterial meningitis in children. When the vaccine is available it should enable physicians largely to avoid the problem of prescribing adequate antibiotic treatment. In recent years, a large percentage of<i>H influenzae</i>organisms have become resistant to ampicillin, the antibiotic of choice for treating these infections. In such cases, the physician has had to fall back on chloramphenicol, with its potential for bone marrow toxicity. <i>Haemophilus influenzae</i>type b (Hib) causes an estimated 15,000 to 20,000 cases of meningitis annually in children. In addition, a similar number of cases of sepsis, epiglottidis, pneumonia, septic arthritis, and osteomyelitis are caused by this organism, points out William S. Jordan, MD, director of the microbiology and infectious
Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases
Authors: Mehtap Bacioglu, Luis F. Maia, Oliver Preische, Juliane Schelle, Anja Apel, Stephan A. Kaeser, Manuel Schweighauser, Timo Eninger, Marius Lambert, Andrea Pilotto, Derya R. Shimshek, Ulf Neumann, Philipp J. Kahle, Matthias Staufenbiel, Manuela Neumann, Walter Maetzler, Jens Kuhle, Mathias Jucker
Journal: Neuron (2016)